Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Common Equity (2020 - 2022)

Historic Common Equity for Atea Pharmaceuticals (AVIR) over the last 3 years, with Q3 2022 value amounting to $663.2 million.

  • Atea Pharmaceuticals' Common Equity rose 1405.71% to $663.2 million in Q3 2022 from the same period last year, while for Sep 2022 it was $663.2 million, marking a year-over-year increase of 1405.71%. This contributed to the annual value of $710.1 million for FY2021, which is 2962.32% up from last year.
  • Per Atea Pharmaceuticals' latest filing, its Common Equity stood at $663.2 million for Q3 2022, which was up 1405.71% from $660.5 million recorded in Q2 2022.
  • In the past 5 years, Atea Pharmaceuticals' Common Equity ranged from a high of $710.1 million in Q4 2021 and a low of -$76.5 million during Q3 2020
  • Over the past 3 years, Atea Pharmaceuticals' median Common Equity value was $586.3 million (recorded in 2021), while the average stood at $439.5 million.
  • Its Common Equity has fluctuated over the past 5 years, first skyrocketed by 119847.85% in 2021, then skyrocketed by 1047.0% in 2022.
  • Atea Pharmaceuticals' Common Equity (Quarter) stood at $547.8 million in 2020, then increased by 29.62% to $710.1 million in 2021, then decreased by 6.6% to $663.2 million in 2022.
  • Its last three reported values are $663.2 million in Q3 2022, $660.5 million for Q2 2022, and $679.9 million during Q1 2022.